Phase 4Status unknown
Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
Multi-center, Randomized, Double-blind, Placebo-controlled Trial of a Live Attenuated Influenza Vaccine in People Aged 3-17
- Sponsor
- Changchun BCHT Biotechnology Co. (Industry)
- Enrolment
- 6,080 planned
- Conditions
- Influenza Prevention
- Interventions
- Influenza Vaccine, Live, Nasal, Freeze-dried; Sterile water for inhalation
- Ages
- children
- Registry
- NCT06280144
Full record on ClinicalTrials.gov
From the registry
To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine. To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine.
Primary outcomes
- Primary influenza protective effect endpoint
History
Study completion
Primary completion
Registered
Started